These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31374478)

  • 1. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
    Lai H; Zeng D; Liu C; Zhang Q; Wang X; Chen T
    Biomaterials; 2019 Oct; 219():119377. PubMed ID: 31374478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-ray sensitive selenium-containing Ru complexes sensitize nasopharyngeal carcinoma cells for radio/chemotherapy.
    Shi C; Yuan Z; Liu T; Chan L; Chen T; Zhao J
    J Mater Chem B; 2023 Jun; 11(24):5607-5618. PubMed ID: 37170629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.
    Berg M; Lundqvist A; McCoy P; Samsel L; Fan Y; Tawab A; Childs R
    Cytotherapy; 2009; 11(3):341-55. PubMed ID: 19308771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.
    Zamai L; Ahmad M; Bennett IM; Azzoni L; Alnemri ES; Perussia B
    J Exp Med; 1998 Dec; 188(12):2375-80. PubMed ID: 9858524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
    Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
    Int J Cancer; 2013 Oct; 133(7):1643-52. PubMed ID: 23504627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down regulation of TRAIL and FasL on NK cells by Cyclosporin A in renal transplantation patients.
    Zhang Y; Cheng G; Xu ZW; Li ZL; Song CJ; Li Q; Chen LH; Yang K; Yang AG; Jin BQ
    Immunol Lett; 2013 Apr; 152(1):1-7. PubMed ID: 23523711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment.
    Chen Q; He L; Li X; Xu L; Chen T
    Biomaterials; 2022 Feb; 281():121371. PubMed ID: 35063740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selenium-ruthenium complex blocks H1N1 influenza virus-induced cell damage by activating GPx1/TrxR1.
    Li Y; Chen D; Su J; Chen M; Chen T; Jia W; Zhu B
    Theranostics; 2023; 13(6):1843-1859. PubMed ID: 37064873
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells.
    Yu Y; Hagihara M; Ando K; Gansuvd B; Matsuzawa H; Tsuchiya T; Ueda Y; Inoue H; Hotta T; Kato S
    J Immunol; 2001 Feb; 166(3):1590-600. PubMed ID: 11160200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.
    Kajitani K; Tanaka Y; Arihiro K; Kataoka T; Ohdan H
    Breast Cancer Res Treat; 2012 Jul; 134(1):139-55. PubMed ID: 22261932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated NK cells kill hepatic stellate cells via p38/PI3K signaling in a TRAIL-involved degranulation manner.
    Li T; Yang Y; Song H; Li H; Cui A; Liu Y; Su L; Crispe IN; Tu Z
    J Leukoc Biol; 2019 Apr; 105(4):695-704. PubMed ID: 30748035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer activity and mechanistic features of a NK cell activating molecule.
    Kim HR; Lee KH; Park SJ; Kim SY; Yang YK; Tae J; Kim J
    Cancer Immunol Immunother; 2009 Oct; 58(10):1691-700. PubMed ID: 19259669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of Human Hepatic Intrasinusoidal CD56
    Hwang S; Han J; Baek JS; Tak E; Song GW; Lee SG; Jung DH; Park GC; Ahn CS; Kim N
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
    Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
    Eur J Immunol; 2013 Jan; 43(1):249-57. PubMed ID: 22996291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
    Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of casein kinase 2 enhances the death ligand- and natural kiler cell-induced hepatocellular carcinoma cell death.
    Kim HR; Kim K; Lee KH; Kim SJ; Kim J
    Clin Exp Immunol; 2008 May; 152(2):336-44. PubMed ID: 18336591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.